Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh (GILD34) Stock Price & Analysis

GILD34 Stock Chart & Stats

R$84.00R$10.01(13.53%)

At close: Oct 30

Day’s Range: BRL 77.70 - BRL 84.00
52-Week Range: BRL 0.00 - BRL 84.00
Previous Close: BRL 73.99
Volume: N/A
Average Volume (3M): 220
Market Cap: BRL 1.15T
Enterprise Value: BRL 920.58B
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): ―
Beta: -0.67
Next Earnings: Feb 04, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: 1.13%

Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh News

Gilead price target raised to $200 from $177 at Scotiabank

Scotiabank analyst Louise Chen raised the firm’s price target on Gilead (GILD) to $200 from $177 and keeps an Outperform rating on the shares. The firm believes the price target

2d agoGILD GIS

Gilead price target raised to $183 from $163 at Morgan Stanley

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $183 from $163 and keeps an Overweight rating on the shares. Published first on TheFly –

2d agoGILD GIS

Gilead price target raised to $190 from $170 at JPMorgan

JPMorgan analyst Chris Schott raised the firm’s price target on Gilead (GILD) to $190 from $170 and keeps an Overweight rating on the shares. Published first on TheFly – the

2d agoGILD GIS

Gilead price target raised to $181 from $158 at Truist

Truist analyst Gregory Renza raised the firm’s price target on Gilead (GILD) to $181 from $158 and keeps a Buy rating on the shares. The company delivered a beat on

2d agoGILD GIS

Gilead price target raised to $175 from $160 at TD Cowen

TD Cowen analyst Tyler Van Buren raised the firm’s price target on Gilead (GILD) to $175 from $160 and keeps a Buy rating on the shares. The firm said Q3

2d agoGILD GIS

Gilead price target raised to $195 from $175 at UBS

UBS raised the firm’s price target on Gilead (GILD) to $195 from $175 and keeps a Buy rating on the shares. Gilead posted a strong Q3 beat and raise driven

2d agoGILD GIS

Gilead price target raised to $175 from $155 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Gilead (GILD) to $175 from $155 and keeps an Overweight rating on the shares. Gilead delivered its largest revenue beat since the

2d agoGILD GIS

Gilead price target raised to $200 from $170 at Needham

Needham raised the firm’s price target on Gilead (GILD) to $200 from $170 and keeps a Buy rating on the shares. The company’s topline Q3 beat was again highlighted by

2d agoGILD GIS

Gilead price target raised to $188 from $165 at Citi

Citi raised the firm’s price target on Gilead (GILD) to $188 from $165 and keeps a Buy rating on the shares. The company’s Q3 report reinforced confidence in the durability

2d agoGILD GIS

Gilead price target raised to $190 from $165 at Wells Fargo

Wells Fargo analyst Mohit Bansal raised the firm’s price target on Gilead (GILD) to $190 from $165 and keeps an Overweight rating on the shares. The firm thinks Gilead’s Q3

2d agoGILD GIS

Gilead Sciences: Hold Rating Maintained as PepStar Acquisition Boosts I&I Pipeline and Price Target Raised to $142

Goldman Sachs analyst Salveen Richter has maintained their neutral stance on GILD stock, giving a Hold rating on October 21. Salveen Richter has given his Hold rating due to a

1w agoGILD GIS

Gilead Buy Rating Reaffirmed as PepStar Deal Bolsters I&I Pipeline; Price Target Maintained at $163

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Gilead Sciences, with a price target of $163.00. Terence Flynn has given his Buy rating

1w agoGILD GIS

Gilead Buy Rating Reaffirmed as Strategic I&I Acquisition Supports Oral Combo Potential; $175 Price Target Maintained

Analyst Michael Yee from UBS maintained a Buy rating on Gilead Sciences and keeping the price target at $175.00. Michael Yee has given his Buy rating due to a combination

1w agoGILD GIS

Gilead: Buy Rating Reiterated on Emvistegrast Momentum, Durable HIV Core and Emerging Oncology Growth; $174 Price Target Maintained

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Gilead Sciences, with a price target of $174.00. Evan Seigerman has given his Buy rating

1w agoGILD GIS

GILD34 FAQ

What was Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh’s price range in the past 12 months?

Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh lowest stock price was R$0.00 and its highest was R$84.00 in the past 12 months.

What is Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh’s market cap?

Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh’s market cap is R$1.15T.

When is Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh’s earnings last quarter?

Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh released its earnings results on Oct 29, 2026. The company reported R$0.001 earnings per share for the quarter.

Is Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh pay dividends?

Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh does not currently pay dividends.

What is Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh’s EPS estimate?

Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh have?

Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh has 14,879,462,000 shares outstanding.

What happened to Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh’s price movement after its last earnings report?

Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh reported an EPS of R$0.001 in its last earnings report. Following the earnings report the stock price went up 13.529%.

Which hedge fund is a major shareholder of Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh?

Currently, no hedge funds are holding shares in BR:GILD34

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh (GILD34) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	15	1	5
Technical Analysis	3	1	5
Moving Averages	12	0	0

Technical Analysis >

Similar Stocks

Stocks similar to BR:GILD34
Company	Price & Change	Follow
BR:AMGN34Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh
BR:BMYB34Bristol-Myers Squibb Company Shs Unsponsored Brazilian Depository Receipt Repr 1 Sh
BR:G1SK34GSK PLC ADR Unsponsored Brazilian Depositary Receipt Repr 0.2 ADR
BR:PFIZ34Pfizer Inc Shs Unsponsored Brazilian Depository Receipts Repr 0.25 Sh
BR:VRTX34Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh

Compare BR:GILD34 Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

GILD34 Stock Chart & Stats

Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh News

Gilead price target raised to $200 from $177 at Scotiabank

Gilead price target raised to $183 from $163 at Morgan Stanley

Gilead price target raised to $190 from $170 at JPMorgan

Gilead price target raised to $181 from $158 at Truist

Gilead price target raised to $175 from $160 at TD Cowen

Gilead price target raised to $195 from $175 at UBS

Gilead price target raised to $175 from $155 at Cantor Fitzgerald

Gilead price target raised to $200 from $170 at Needham

Gilead price target raised to $188 from $165 at Citi

Gilead price target raised to $190 from $165 at Wells Fargo

Gilead Sciences: Hold Rating Maintained as PepStar Acquisition Boosts I&I Pipeline and Price Target Raised to $142

Gilead Buy Rating Reaffirmed as PepStar Deal Bolsters I&I Pipeline; Price Target Maintained at $163

Gilead Buy Rating Reaffirmed as Strategic I&I Acquisition Supports Oral Combo Potential; $175 Price Target Maintained

Gilead: Buy Rating Reiterated on Emvistegrast Momentum, Durable HIV Core and Emerging Oncology Growth; $174 Price Target Maintained

GILD34 FAQ

Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh (GILD34) Earnings & Revenues

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium